497 related articles for article (PubMed ID: 17694092)
1. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design.
Hodawadekar SC; Marmorstein R
Oncogene; 2007 Aug; 26(37):5528-40. PubMed ID: 17694092
[TBL] [Abstract][Full Text] [Related]
2. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
Yang XJ; Seto E
Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
[TBL] [Abstract][Full Text] [Related]
3. Small molecule modulators in epigenetics: implications in gene expression and therapeutics.
Swaminathan V; Reddy BA; Ruthrotha Selvi B; Sukanya MS; Kundu TK
Subcell Biochem; 2007; 41():397-428. PubMed ID: 17484138
[TBL] [Abstract][Full Text] [Related]
4. Histone acetyl transferases as emerging drug targets.
Dekker FJ; Haisma HJ
Drug Discov Today; 2009 Oct; 14(19-20):942-8. PubMed ID: 19577000
[TBL] [Abstract][Full Text] [Related]
5. Regulation of protein turnover by acetyltransferases and deacetylases.
Sadoul K; Boyault C; Pabion M; Khochbin S
Biochimie; 2008 Feb; 90(2):306-12. PubMed ID: 17681659
[TBL] [Abstract][Full Text] [Related]
6. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic regulation of airway inflammation.
Adcock IM; Tsaprouni L; Bhavsar P; Ito K
Curr Opin Immunol; 2007 Dec; 19(6):694-700. PubMed ID: 17720468
[TBL] [Abstract][Full Text] [Related]
8. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
9. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
10. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.
Somoza JR; Skene RJ; Katz BA; Mol C; Ho JD; Jennings AJ; Luong C; Arvai A; Buggy JJ; Chi E; Tang J; Sang BC; Verner E; Wynands R; Leahy EM; Dougan DR; Snell G; Navre M; Knuth MW; Swanson RV; McRee DE; Tari LW
Structure; 2004 Jul; 12(7):1325-34. PubMed ID: 15242608
[TBL] [Abstract][Full Text] [Related]
11. HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics.
Gallinari P; Di Marco S; Jones P; Pallaoro M; Steinkühler C
Cell Res; 2007 Mar; 17(3):195-211. PubMed ID: 17325692
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors.
Marks PA; Richon VM; Miller T; Kelly WK
Adv Cancer Res; 2004; 91():137-68. PubMed ID: 15327890
[TBL] [Abstract][Full Text] [Related]
13. Prospects: histone deacetylase inhibitors.
Dokmanovic M; Marks PA
J Cell Biochem; 2005 Oct; 96(2):293-304. PubMed ID: 16088937
[TBL] [Abstract][Full Text] [Related]
14. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
15. Histone modification enzymes: novel targets for cancer drugs.
Kristeleit R; Stimson L; Workman P; Aherne W
Expert Opin Emerg Drugs; 2004 May; 9(1):135-54. PubMed ID: 15155140
[TBL] [Abstract][Full Text] [Related]
16. Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A.
Codd R; Braich N; Liu J; Soe CZ; Pakchung AA
Int J Biochem Cell Biol; 2009 Apr; 41(4):736-9. PubMed ID: 18725319
[TBL] [Abstract][Full Text] [Related]
17. Reversible acetylation of chromatin: implication in regulation of gene expression, disease and therapeutics.
Selvi RB; Kundu TK
Biotechnol J; 2009 Mar; 4(3):375-90. PubMed ID: 19296442
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases: complex transducers of nuclear signals.
Johnson CA; Turner BM
Semin Cell Dev Biol; 1999 Apr; 10(2):179-88. PubMed ID: 10441071
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors: biology and mechanism of action.
Mehnert JM; Kelly WK
Cancer J; 2007; 13(1):23-9. PubMed ID: 17464243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
